We’re still, I think, learning a little bit about specificity and sensitivity, you know, even with the tissue-based assays. We have other work not presented here, but that sensitivity definitely changes depending on metastatic location and sometimes on the somatic mutations of that tumor. We have not tested this new tissue-agnostic methylation-based assay in enough cases head-to-head to really make a comment on the direct comparison, but we think that it is going to be very similar...
We’re still, I think, learning a little bit about specificity and sensitivity, you know, even with the tissue-based assays. We have other work not presented here, but that sensitivity definitely changes depending on metastatic location and sometimes on the somatic mutations of that tumor. We have not tested this new tissue-agnostic methylation-based assay in enough cases head-to-head to really make a comment on the direct comparison, but we think that it is going to be very similar.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
